ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 172

Is the Epidemiology of Rheumatoid Arthritis (RA) Changing? Results from a Population-based Incidence Cohort of RA Patients, 2005-2014

Elena Myasoedova1, John Davis 1, Eric Matteson 2 and Cynthia Crowson 3, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, 3Mayo Clinic Rochester, Rochester

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis (RA) and epidemiologic methods

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Epidemiology & Public Health Poster I: RA

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The incidence and prevalence of rheumatoid arthritis (RA) vary substantially between populations in different geographic areas and over time. Recent trends in RA incidence in US populations are unknown. We aimed to examine trends in the incidence of RA from 2005 to 2014 as compared to the previous decades.

Methods: We evaluated RA incidence trends in a population-based inception cohort of individuals 18 years of age and older who first fulfilled the ACR 1987 classification criteria for RA between 1/1/1985 and 12/31/2014. While both rheumatoid factor (RF) and cyclic citrullinated peptide antibody (anti-CCP) were considered for criteria fulfillment when available, incidence rates were calculated for RF positive vs negative without inclusion of anti-CCP to allow fair comparison of incidence rates over 3 decades during which anti-CCP testing rates were on the rise. Incidence rates were estimated and were age-and sex-adjusted to the white population in the US in 2010. Trends in incidence rates were examined using Poisson regression methods.

Results: The 2005-2014 incidence cohort comprised 428 patients: mean age 55.4 years, 68% female, 51% RF positive, 50% anti-CCP positive (Table 1). There was no statistically significant difference in age at RA incidence, sex distribution or race in 2005-2014 cohort vs 1995-2004 and 1985-1994 cohorts. Smoking rates declined and obesity rates increased from earlier decades to more recent years. Patients in the 2005-2014 cohort were more likely to develop an erosion in the first year of RA incidence as compared to the previous decades.

Table 2 shows RA incidence rates per 100,000 population for 3 most recent decades and by RF status. The overall age- and sex-adjusted annual RA incidence in 2005-2014 was 43/100,000 population with age-adjusted incidence in women 55/100,000 population and 29/100,000 population in men. These estimates were similar to the 1995-2004 decade. There was a decline in the incidence of RF positive RA in 2005-2014 compared to the previous 2 decades (p=0.006), with a corresponding increase in RF negative cases (p< 0.001, Table 2).

Conclusion: The incidence of RA overall during the 2005-2014 period remained similar to the previous decade. An increase in RF-negative RA disease and decrease in RF positive RA was found using 1987 ACR criteria. Changing prevalence of environmental factors, such as smoking, obesity and others, may have contributed to these trends. Whether these trends represent a changing serological profile of RA requires further investigation.

Table 1. Patient characteristics by decade of RA incidence

Table 2. Incidence rates by 1987 ACR criteria per 100,000 population -95% CI-


Disclosure: E. Myasoedova, Pfizer, 2; J. Davis, Abbvie, 5, Pfizer, 2, 5, Sanofi Genzyme, 5; E. Matteson, Boehringer Ingelheim, 5, Pfizer, 2, Sun Pharmaceuticals, 2; C. Crowson, Crescendo Bioscience, 5, Crescendo BioScience Inc., 5, Crescendo Bioscience Inc., 5, Crescendo Biosciences inc., 5, Pfizer, 2.

To cite this abstract in AMA style:

Myasoedova E, Davis J, Matteson E, Crowson C. Is the Epidemiology of Rheumatoid Arthritis (RA) Changing? Results from a Population-based Incidence Cohort of RA Patients, 2005-2014 [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/is-the-epidemiology-of-rheumatoid-arthritis-ra-changing-results-from-a-population-based-incidence-cohort-of-ra-patients-2005-2014/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-the-epidemiology-of-rheumatoid-arthritis-ra-changing-results-from-a-population-based-incidence-cohort-of-ra-patients-2005-2014/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology